Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

We recently published a list of Jim Cramer Reacts to the Surprise Market Surge and Highlights 8 Key Stocks In this article, ...

The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

Key Takeaways Pfizer said it will discontinue development of oral daily weight-loss treatment danuglipron.A Phase 3 trial ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

Pfizer Inc. dejará de desarrollar una píldora contra la obesidad que ha sido seguida de cerca por los inversores, un duro ...

Pfizer will stop developing an obesity pill that has been closely watched by investors, a severe blow in its efforts to ...

Pfizer has made competing in the obesity market central to its post-Covid comeback plan. As demand for coronavirus vaccines ...

Pfizer said it would stop studying the pill after a participant in one of its trials experienced a drug-induced liver injury.